Business
GoodRx Expands Access to Eli Lilly and Company’s New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide
Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx Brief Summary: GoodRx is expanding access to the newly FDA-approved
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"\nEligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx\n\n\nBrief Summary:\n\n\n\nGoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron)\n\n\n\nEligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx\n\n\n\nGoodRx is also offering self-pay pricing for Zepbound® (tirzepatide) KwikPen® starting at $299 per month\n\n\n\nFoundayo and Zepbound KwikPen are available through GoodRx’s nationwide pharmacy network\n\n\n\nGoodRx is helping pharmaceutical manufacturers deliver consumer-direct pricing at scale from day one\n\n\n\n SANTA MONICA, Calif.--(BUSINESS WIRE)--\nGoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment.\n\n\nGoodRx is also expanding access to Zepbound® (tirzepatide) KwikPen®, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide. Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways.\n\n\n“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, President and CEO of GoodRx. “As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”\n\n\n“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Eli Lilly and Compan...